The FDA Is Running on Fumes, and Biotech Is Paying the Price
Praxis Precision Medicine's epilepsy drug just got a three-month FDA delay, and it's far from the only biotech feeling the squeeze. With roughly 3,500 FDA employees cut since 2025, the agency's review machine is straining under its own weight.
The FDA just pushed back its decision on a drug for kids with severe epilepsy. Three months, just like that. And while the delay has a perfectly reasonable technical explanation, the timing tells a bigger story: the agency that approves America's medicines is stretched thinner than it's been in years.
Praxis Precision Medicine got the news late last week. Its drug relutrigine, which targets rare and devastating developmental epileptic encephalopathies (DEEs) in children, had its FDA decision date moved from September 27 to December 27, 2026. The stock dropped about 7% in after-hours trading.
The official reason? Praxis had submitted additional sensitivity analyses of its existing clinical data. The FDA classified that as a "major amendment," which is regulatory speak for: "You gave us more homework, so we're giving ourselves more time." Under standard rules, the agency can tack on up to three months when that happens.
No new safety concerns. No request for another clinical trial. No manufacturing red flags. On paper, this looks routine.
But "routine" at the FDA doesn't feel the same as it used to.
3,500 Fewer People Doing the Same Amount of Work
In April 2025, roughly 3,500 FDA employees were cut as part of sweeping HHS workforce reductions tied to government efficiency initiatives. That's about a 20% reduction in the agency's headcount. Another round brought the total to nearly 4,300 positions lost through early 2026, according to Office of Personnel Management data.
Think of it like a restaurant firing a fifth of its kitchen staff on a Friday night. The orders keep coming in at the same pace. Maybe even faster. The cooks who remain work harder, but eventually the wait times creep up, plating gets sloppy, and someone sends out the wrong entrée.
At FDA, the equivalents are piling up. Scientists in device and tobacco review divisions have reportedly struggled to meet Congressional deadlines. Email responses that used to take days now take weeks. Mid-level managers with decades of institutional knowledge walked out the door and took their expertise with them.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The drug review divisions were supposedly shielded from the worst cuts. But "shielded" is relative when the people who process fees, manage records, schedule advisory committee meetings, and coordinate between divisions are all part of the same ecosystem.
The 2025 Illusion
If you just looked at the scoreboard, you'd think everything was fine. An analysis of all 46 novel drugs and biologics approved by FDA's CDER in 2025 found the FDA met nearly all of its user-fee deadline goals. Only two applications took longer than 12 months, and both extensions were triggered by new data submissions, not staffing shortfalls.
But that headline number is a bit like saying a student passed all their exams while ignoring that they stopped sleeping, quit their extracurriculars, and haven't done laundry in a month. The FDA kept its review clocks ticking in 2025 by triaging aggressively: fewer guidance documents, postponed meetings with drug sponsors, and deferred policy work that doesn't have a statutory deadline attached.
A former director of the FDA's Center for Biologics told BMO Capital Markets that the real damage from those 3,500 layoffs would show up in 2026 and 2027, as backlogs compound and remaining staff burn out. Congressional oversight staff went further, warning that missed user-fee benchmarks were "almost certain" by fiscal year-end.
Praxis Isn't Alone
The Praxis delay is notable, but it's far from isolated. A growing list of biotech companies have seen their FDA timelines slip in recent months:
Denali Therapeutics had its decision date for tividenofusp alfa pushed from January to April 2026 after a major amendment. Disc Medicine saw a two-week delay on its rare blood disorder drug. Sanofi, Boehringer Ingelheim, and Eli Lilly all had review timelines extended for various programs. Travere Therapeutics got bumped to April 13, and its stock took a hit.
Perhaps the most sobering case: Kezar Life Sciences, where a four-month FDA delay reportedly contributed to the company shutting down entirely. For small biotechs burning cash while waiting on a single regulatory decision, every extra month can be existential.
The Wall Street Journal reported that at least one small biotech developing a treatment for a life-threatening genetic respiratory disease hadn't received FDA feedback on a trial amendment and was considering moving its clinical work to Europe. That's not a rounding error. That's a canary in the coal mine.
What This Means for Praxis Specifically
Back to the company at the center of today's story. Despite the delay, most analysts covering Praxis aren't panicking. The relutrigine application still has Priority Review status, along with Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations. Those labels carry weight; they signal that the FDA considers this drug both important and differentiated.
Jefferies analysts have previously pegged relutrigine's approval probability at over 70%, with potential peak sales north of $2.5 billion. The EMBOLD trial results were so strong that the Data Monitoring Committee halted the study early for positive efficacy, as continuing a placebo comparison would have been unethical. Multiple firms have reiterated Buy ratings.
Meanwhile, Praxis has a second NDA under review: ulixacaltamide for essential tremor, with a decision date of January 29, 2027. That one holds Breakthrough Therapy Designation too, and so far its timeline hasn't budged. The company also expects topline Phase 3 data from its vormatrigine epilepsy program in Q2 2026 and broader DEE data from the EMERALD trial in Q4.
So the pipeline is deep, and the setback is measured in months, not years. But for a company that doesn't yet generate meaningful revenue (some models don't have Praxis reaching profitability until after 2028), every quarter matters.
The Bigger Picture Is the Real Story
The Praxis delay, taken alone, is a footnote. Taken alongside Denali, Disc Medicine, Kezar, Travere, and the unnamed biotech eyeing Europe, it starts to look like a pattern.
The practical advice from regulatory experts boils down to this: model two scenarios. The base case where the FDA hits its target date, and the risk case where you get a three-to-six month extension driven by resource constraints. Build that buffer into your cash planning, your launch prep, and your investor messaging.
For patients with rare epilepsies waiting on relutrigine, or the millions of essential tremor sufferers hoping ulixacaltamide lives up to its data, the math is simpler. A three-month delay means three more months of unmet need.
The FDA didn't create this problem on purpose. But 3,500 fewer employees is 3,500 fewer employees, and the laws of physics (or at least bureaucracy) still apply. You can only squeeze so much throughput from a shrinking workforce before the cracks start showing.
They're showing.
Clinical & Regulatory
5 min read
The Eye Disease Drug That Wants to Ditch the IV Pole
Genentech just scored FDA Priority Review for Enspryng as the first at-home, self-injectable treatment for thyroid eye disease. In a market long dominated by a single $300K IV therapy, the race to give patients a shot they can take in their pajamas is heating up fast.
